CIK 0001642380 · Non-accelerated filer<br>Smaller reporting company
Insight Molecular Diagnostics Inc.
Sign in to watch- Ticker
- IMDX
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 271041563
- Phone
- 949-409-7600
- Business address
- 2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217
- Former names
- OncoCyte Corp, Oncocyte Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-03 | Arno Andrew Director | Grant or award | +141,084 | $0.35 | $50K | 156,084 |
| 2023-04-03 | Arno Andrew Director | Grant or award | +141,084 | $0.35 | $50K | 156,084 |
| 2023-04-03 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | +26,827,638 | $0.30 | $8.1M | 50,181,335 |
| 2023-04-03 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | +0 | 50,181,335 | ||
| 2023-03-06 | PURA VIDA INVESTMENTS, LLC 10% owner | Other disposition | −3,890,111 | 4,589,571 | ||
| 2023-03-06 | PURA VIDA INVESTMENTS, LLC 10% owner | Other disposition · Warrant to purchase common stock | −440,964 | 517,245 | ||
| 2023-03-06 | PURA VIDA INVESTMENTS, LLC 10% owner | Other disposition | −3,890,111 | 4,589,571 | ||
| 2023-02-24 | Riggs Josh CEO | Grant or award · Option to Purchase Common Stock | +116,426 | 116,426 | ||
| 2023-02-24 | John Anish M. Chief Financial Officer | Grant or award · Option to Purchase Common Stock | +121,381 | 121,381 | ||
| 2023-01-17 | Riggs Josh Interim CEO | Grant or award · Option to Purchase Common Stock | +257,485 | 257,485 | ||
| 2023-01-17 | Liu James Yang Controller, PAO | Grant or award · Option to Purchase Common Stock | +57,065 | 57,065 | ||
| 2023-01-17 | John Anish M. Chief Financial Officer | Grant or award · Option to Purchase Common Stock | +250,466 | 250,466 | ||
| 2022-12-23 | Arno Andrew Director | Purchase | +250,000 | $0.35 | $88K | 532,049 |
| 2022-12-23 | Gutfreund John Peter Director | Purchase | +75,000 | $0.33 | $25K | 75,000 |
| 2022-12-22 | KINGSLEY ALFRED D Director | Purchase | +25,000 | $0.29 | $7K | 439,111 |
| 2022-12-21 | Ross Douglas T. Former CSO | Grant or award | +213,797 | 234,114 | ||
| 2022-12-16 | Ross Douglas T. Former CSO. | Returned to the company · Option to Purchase Common Stock | −83,334 | 166,666 | ||
| 2022-12-16 | Ross Douglas T. Former CSO. | Returned to the company · Option to Purchase Common Stock | −143,438 | 111,562 | ||
| 2022-12-16 | Ross Douglas T. Former CSO. | Returned to the company · Option to Purchase Common Stock | −100,000 | 0 | ||
| 2022-12-16 | Ross Douglas T. Former CSO. | Returned to the company · Option to Purchase Common Stock | −100,000 | 0 |
Page 6 of 12 · 222 trades